Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALLik: Ponatinib plus chemotherapy for BCR/ABL1-like acute lymphoblastic leukemia
2022-000633-17Phase 2Active
- Sponsor
- GIMEMA
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: MRD negativity rate at TP2 (after 3 cycles). Started Jun 2022; status: active.
02
Drugs
ponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2022-000633-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000633-17.